Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Combined testing sits at the center of this question for families navigating dementia.
Combined brain disease testing refers to a new approach that uses a single blood test combined with artificial intelligence to identify which type of brain disease a patient may have. Rather than requiring multiple specialized imaging tests or invasive procedures, patients can now get screened for several dementia-related conditions with a simple blood draw. This represents one of the most significant advances in neurology in recent years—doctors can now distinguish between Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, and dementia with Lewy bodies with 92.3% accuracy using just a blood sample analyzed by AI algorithms.
The shift to blood-based testing means that a patient experiencing memory loss or cognitive changes no longer needs to schedule a PET scan that takes hours and may require contrast dye, or worse, undergo a lumbar puncture—a spinal tap that carries real risks of infection and complications. Instead, a nurse draws a small vial of blood, usually during a routine office visit, and AI analyzes biomarkers in the blood that reveal which brain disease, if any, is present. For many patients, this single test can replace what previously required multiple expensive imaging studies and specialist consultations.
Table of Contents
- What Are Brain Biomarkers and How Do They Enable Diagnosis?
- The Evolution From Invasive Testing to Blood-Based Screening
- Which Brain Diseases Can Combined Testing Identify?
- What to Expect When Getting Blood-Based Testing
- Understanding Test Accuracy, Limitations, and What Results Mean
- New Treatment Options Now Available Based on Testing Results
- The Future Outlook for Brain Disease Diagnosis
- Conclusion
What Are Brain Biomarkers and How Do They Enable Diagnosis?
brain biomarkers are measurable indicators in the blood that reflect what’s happening inside the brain. For decades, the only way to definitively diagnose Alzheimer’s or other dementias was to wait for autopsy or to use expensive imaging like PET scans that directly visualize amyloid and tau proteins accumulating in brain tissue. Now, researchers have identified specific proteins that leak from the brain into the bloodstream when neurodegeneration occurs—including phosphorylated tau variants, amyloid-beta 42, and neurofilament light chain. When these biomarkers appear in the blood, they signal that pathological changes are happening in the brain.
The AI component of combined testing adds critical diagnostic power. Once blood samples are collected and biomarkers are measured, machine learning algorithms trained on thousands of patient cases can recognize patterns in the biomarker combinations that distinguish one disease from another. A patient with high phosphorylated tau-181 paired with specific amyloid patterns might have Alzheimer’s disease, while someone with different biomarker ratios might have Lewy body dementia instead. The algorithm integrates multiple data points simultaneously in ways that human interpretation alone would struggle to achieve consistently, which is why the combined test achieves such high accuracy.
The Evolution From Invasive Testing to Blood-Based Screening
For decades, dementia diagnosis relied on invasive or resource-intensive methods. A neurologist suspecting Alzheimer’s would order a PET scan—a nuclear imaging test that requires patients to receive an IV injection of radioactive tracer, then lie still in a machine for an hour while it images protein accumulation in the brain. The cost runs into thousands of dollars, equipment availability is limited to major medical centers, and the radiation exposure, while small, still exists. For patients suspected of having Lewy body dementia or other conditions, a lumbar puncture might be ordered to directly examine cerebrospinal fluid. This procedure carries real risks: meningitis, bleeding, infection, and severe post-procedure headaches that can last for days. Blood-based biomarker testing eliminates these barriers almost entirely.
There is no radiation, no spinal puncture risk, no need for specialized imaging equipment, and no post-procedure complications. A patient can walk into their primary care doctor’s office, get blood drawn, and leave. The test can be run in a hospital lab or even processed through mail-order services in some cases. This accessibility matters enormously for early detection—patients who suspect cognitive problems are far more willing to pursue screening when it involves a simple blood draw rather than a time-consuming imaging study or invasive procedure. However, it’s important to understand that blood tests detect pathology; they don’t replace clinical evaluation. A patient still needs a neurologist or cognitive specialist to interpret results in the context of their actual symptoms and cognitive testing, because some people have brain pathology visible on biomarkers but haven’t yet developed symptoms.
Which Brain Diseases Can Combined Tests Identify?
Combined brain disease testing can currently differentiate between five distinct diagnostic categories: Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, dementia with Lewy bodies, and healthy brain aging. Each disease involves different patterns of protein accumulation and neurodegeneration, which create distinct biomarker signatures in the blood. A patient presenting with memory loss and cognitive decline might be concerned they have Alzheimer’s, but combined testing might reveal that their biomarker pattern actually matches frontotemporal dementia, which presents differently and requires different treatment approaches and family counseling. Parkinson’s disease, often thought of primarily as a movement disorder, is also reliably identified through combined testing because it involves accumulation of alpha-synuclein protein in the brain that shows up in blood biomarkers.
Dementia with Lewy bodies produces a different biomarker pattern than Parkinson’s dementia, even though both involve Lewy bodies—a distinction that matters for treatment selection. Frontotemporal dementia, which often strikes patients in their 50s and 60s—younger than typical Alzheimer’s onset—has unique biomarker signatures. And critically, the test can distinguish between people who have brain pathology but remain cognitively normal (preclinical disease) and those with healthy aging. This matters because someone with Alzheimer’s pathology but no symptoms yet might be a candidate for early intervention with newer disease-modifying drugs, while someone with healthy biomarkers can be reassured and monitored without unnecessary treatment.
What to Expect When Getting Blood-Based Testing
The testing process itself is straightforward. A patient makes an appointment with their neurologist, primary care doctor, or other healthcare provider. During the visit, the provider discusses symptoms, reviews medical history, and performs cognitive screening tests—this clinical evaluation is essential context for interpreting results. The doctor then orders the combined brain disease blood test, and a phlebotomist draws one or two small vials of blood, the same as they would for routine blood work. The patient leaves the office and can immediately resume normal activities with no restrictions or recovery time.
After the blood draw, the sample is sent to a laboratory where biomarkers are quantified using specialized equipment. These measurements are then entered into an AI-powered algorithm that compares the patient’s biomarker pattern against patterns associated with each disease type. Results typically come back within one to two weeks. When the results are ready, the patient meets with their doctor again to discuss findings. If biomarkers indicate disease pathology, the conversation shifts to next steps: What stage of disease is the patient in? What treatment options exist? Should imaging be done to confirm? Should genetic testing be performed? What symptoms might develop, and what should the patient watch for? If biomarkers are normal, the focus turns to reassurance, lifestyle factors that support brain health, and any continued monitoring needed based on symptoms.
Understanding Test Accuracy, Limitations, and What Results Mean
The 92.3% accuracy rate for combined brain disease testing is impressive, but it’s crucial to understand what “accuracy” means in this context. This figure reflects how often the test correctly identifies which disease category a patient belongs to when examined in research settings with known cases. In real-world clinical practice, accuracy depends on several factors: the quality of the blood sample, the specific biomarker cutoffs the lab uses, and whether the patient has early preclinical disease or advanced disease. Early-stage pathology can sometimes produce borderline biomarker levels that are harder to classify definitively, while advanced disease typically shows clear biomarker signatures. A critical limitation is that combined testing reveals brain pathology but doesn’t always predict the future.
Some people have Alzheimer’s-level pathology in their brains but remain cognitively normal—they may never develop dementia symptoms in their lifetime. Conversely, a patient with significant cognitive symptoms might have biomarker results that don’t fit neatly into any disease category, requiring additional clinical investigation. Additionally, this test works best for neurodegenerative diseases involving amyloid, tau, and synuclein pathology. It doesn’t reliably detect vascular dementia (caused by stroke), dementia from traumatic brain injury, or cognitive decline caused by depression, thyroid disease, or vitamin deficiency. A patient with a “negative” or “normal” biomarker result doesn’t necessarily have a healthy brain if they’re experiencing real cognitive decline—other causes must be investigated. Insurance coverage for combined testing varies; some insurers cover it, while others consider it investigational and require out-of-pocket payment.
New Treatment Options Now Available Based on Testing Results
Two FDA-approved medications have emerged that specifically treat Alzheimer’s disease by reducing amyloid burden in the brain: lecanemab (brand name Leqembi) and donanemab (brand name Kisunla). These are the first disease-modifying treatments shown to slow cognitive decline in early-stage Alzheimer’s disease. If combined brain disease testing reveals Alzheimer’s pathology in a patient with mild cognitive impairment, they may be a candidate for one of these medications. Lecanemab requires IV infusions every two weeks for about 18 months, while clinical trial data shows it slows cognitive decline by roughly 27% over 18 months—a meaningful slowing compared to the natural progression of untreated disease.
Donanemab is administered via IV infusions on a less frequent schedule and shows similar benefits. These treatments do carry risks, including amyloid-related imaging abnormalities (ARIA), which are brain changes visible on MRI that can include microhemorrhages or brain swelling. For most patients, these changes cause no symptoms, but in some cases they can produce symptoms. Patients on these medications require regular MRI monitoring and need to be carefully screened for eligibility. A patient learning from combined testing that they have Alzheimer’s pathology should have a detailed conversation with their neurologist about whether they’re a candidate for these treatments, considering their age, disease stage, ability to tolerate infusions, and willingness to undergo monitoring MRIs.
The Future Outlook for Brain Disease Diagnosis
Combined brain disease testing represents a fundamental shift in how neurology approaches diagnosis. What once required imaging equipment, radiation, invasive procedures, and high costs is becoming a simple, repeatable, accessible blood test. This shift parallels how other medical specialties have evolved—cardiology moved toward troponin blood tests instead of always relying on EKGs and imaging; oncology increasingly uses liquid biopsies to detect cancer earlier. As AI algorithms refine further and larger datasets train these systems, diagnostic accuracy will likely improve even beyond the current 92.3%.
Eventually, combined testing may become a routine screening test offered to older patients as part of annual physicals, similar to how blood cholesterol tests are offered today. Research is simultaneously advancing toward multimodal testing—combining blood biomarkers with brain imaging, genetic testing, and clinical assessments into integrated diagnostic platforms. Ongoing studies like UCSD’s clinical trials exploring transcranial magnetic stimulation combined with telehealth therapy for brain injury suggest future approaches will layer multiple intervention types for better outcomes. The democratization of brain disease diagnosis through accessible blood tests means earlier detection, earlier intervention with disease-modifying therapies, and better outcomes for patients willing to seek screening.
Conclusion
Combined brain disease testing offers patients a straightforward, non-invasive path to understanding whether they have developing brain disease and, if so, which specific condition. The ability to distinguish between Alzheimer’s, Parkinson’s, frontotemporal dementia, and dementia with Lewy bodies through a single blood draw analyzed by AI eliminates the need for the expensive imaging and invasive procedures that previously defined dementia diagnosis. For patients experiencing memory concerns or cognitive changes, this test can provide clear answers quickly.
If you’re concerned about cognitive changes, a conversation with your doctor about combined brain disease testing is a reasonable next step. Bring a record of specific symptoms you’ve noticed, any relevant family history of dementia, and questions about what testing would involve in your specific situation. Understanding your brain health status—whether through reassurance that biomarkers are normal or through identification of treatable pathology—empowers you to make informed decisions about your healthcare and potentially access new disease-modifying treatments during the window when they’re most effective.
You Might Also Like
- Why Patients Should Be Cautious About Experimental Dementia Treatments
- What Middle-Aged Adults Should Know About Dementia Warning Signs
- How Neurodegenerative Disease Testing Is Converging
Related reading
- how Alzheimer’s Care Promises Can Become Emotionally Complicated
- why Long-Term Care Decisions Are So Painful
- could Better Support Help Families Delay Nursing Home Placement
- what Caregivers Wish They Knew Before Dementia Progressed
- how One Caregiver Story Can Help Other Alzheimer’s Families
For more on this topic, see CDC — Alzheimer’s and Dementia.
